US health official: Trump 'rushing blindly into a potentially dangerous situation' with unproven drug

Whistleblower Rick Bright alleges he was reassigned to a lesser role because he resisted pressure to allow widespread use of hydroxychloroquine.

The Trump administration failed to prepare for the onslaught of coronavirus, then sought a quick fix by trying to rush an unproven drug to patients, a senior government scientist has alleged in a whistleblower complaint.

Rick Bright, former director of the Biomedical Advanced Research and Development Authority, alleges he was reassigned to a lesser role because he resisted political pressure to allow widespread use of hydroxychloroquine, a malaria drug pushed by Donald Trump.